Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status:
Recruiting
Trial end date:
2023-07-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well Avatar-directed chemotherapy works in treating patients
with ovarian, primary peritoneal, or fallopian tube cancer that does not respond to platinum
anti-cancer drugs. Drugs used in chemotherapy, such as paclitaxel, gemcitabine hydrochloride,
pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may
interfere with the ability of tumor cells to grow and spread. Using an Avatar, a living tumor
sample with similar genetic characteristics to the original tumor, may help determine which
chemotherapy is most effective.